ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1677

May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?

Rosaria Talarico1, Chiara Stagnaro2, Claudia Ferrari3, Anna d'Ascanio4, Chiari Tani2, Chiara Baldini2, Marta Mosca3 and Stefano Bombardieri2, 1Rheumatology Unit, Pisa, Italy, 2University of Pisa, Rheumatology Unit, Pisa, Italy, 3Rheumatology Unit, University of Pisa, Pisa, Italy, 4Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that affect large and medium-sized arterial vessels. Growing data shown that almost one-third of the patients with GCA develop serious peripheral vascular complications during long-term follow up, and it seems that unrecognized extra-cranial involvement may be even more common. 

The primary aim of this study was to explore if there are different clinical entities in a cohort of patients with GCA (i.e. symptoms compatible with cranial GCA and large-vessel GCA); a secondary aim was to evaluate long-term outcome of GCA patients with at list 5 years of follow-up.

Methods: Two hundred and ten GCA patients (34 males and 176 females, mean ± SD age 77±8 years) were retrospectively studied. Clinical symptoms at disease onset and during the follow-up, time delay until diagnosis, as well as laboratory findings at the time of diagnosis, therapeutic approach were retrospective evaluated. In order to characterized the different disease entities, overall clinical symptoms were evaluated by means of a spectrum analysis. Moreover, we evaluated long-term outcomes in patients with a minimum follow-up of 5 years. We have defined as disease flare any further clinical manifestation compatible with the clinical spectrum of GCA and/or an increase of ESR ≥ 40 mm/hour, not otherwise justifiable, that required higher doses or new introduction of GC therapy.

Results: The most frequent clinical manifestations presented at the onset included: new onset headache and/or scalp pain 77%, constitutional symptoms 46%, jaw claudicatio 36%, vision loss 34%, abnormal temporal artery on examination 32%, dizziness 29%, neuropsychiatric symptoms 29%, cough not otherwise justifiable 10%, cerebrovascular accidents 6% and hearing loss 5%. Irreversible blindness was reported in 7% of patients, mainly due to a latency period between onset and treatment of ≥ 2 months. Temporal artery biopsy was performed in 160/210 of patients, resulting positive in 58%. Globally, about 26% of subjects (55, M/F: 9/46, mean ± SD age 71±7 years) was characterized by a clinical profile compatible with extra-cranial GCA. In all case, extra-cranial involvement was confirmed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and/or angiography. Moreover, patients who presented symptoms compatible with large-vessel GCA were characterised by a more relapsing course compared with patients with cranial involvement GCA profile.

Conclusion: According literature data, our results confirm that GCA may be composed by more than one single entity. Extra cranial involvement due to GCA must be must be promptly recognized, because it probably may require a different prognostic and therapeutic approach.


Disclosure:

R. Talarico,
None;

C. Stagnaro,
None;

C. Ferrari,
None;

A. d’Ascanio,
None;

C. Tani,
None;

C. Baldini,
None;

M. Mosca,
None;

S. Bombardieri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/may-giant-cell-arteritis-be-characterized-by-different-clinical-entity-and-long-term-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology